CoChat

Therapygenetics in mindfulness-based cognitive therapy: do genes have an impact on therapy-induced change in real-life positive affective experiences?

Open access
Bakker, J M, Lieverse, R, Menne-Lothmann, C, Viechtbauer, W, Pishva, E, Kenis, G, Geschwind, N, Peeters, F, van Os, J, Wichers, M · 2014 · Translational Psychiatry
Cited by 22

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Positive affect (PA) has an important role in resilience against depression and has been shown to increase with mindfulness-based cognitive therapy (MBCT). To elucidate the underlying mechanisms of change in PA as well as develop insights that may benefit personalized medicine, the current study examined the contribution of genetic variation to individual differences in change in PA in response to MBCT. Individuals (n=126) with residual depressive symptoms were randomized to either an MBCT group or treatment as usual. PA was assessed using experience sampling methodology (ESM). Single-nucleotide polymorphisms (SNPs) in genes known to be involved in reward functioning were selected. SNPs in the genes for brain-derived neurotrophic factor (BDNF), the muscarinic acetylcholine receptor M2 (CHRM2), the dopamine receptor D4 (DRD4) and the μ1 opioid receptor (OPRM1) significantly moderated the impact of treatment condition over time on PA. Genetic variation in the genes for CHRM2 and OPRM1 specifically had an impact on the level of PA following MBCT. The current study shows that variation in response to MBCT may be contingent on genetic factors associated with the regulation of PA. These findings contribute to our understanding of the processes moderating response to treatment and prediction of treatment outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/tp.2014.23

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 61

  1. Tugade MM, Fredrickson BL . Resilient individuals use positive emotions to bounce back from negative emotional experiences. J Pers Soc Psychol 2004; 86: 320–333. · DOI · Paper page
  2. Jacobs N, van Os J, Derom C, Thiery E, Delespaul P, Wichers M . Neuroticism explained? From a non-informative vulnerability marker to informative person-context interactions in the realm of daily life. Br J Clin Psychol 2011; 50: 19–32. · DOI · Paper page
  3. Eley TC, Hudson JL, Creswell C, Tropeano M, Lester KJ, Cooper P et al. Therapygenetics: the 5HTTLPR and response to psychological therapy. Mol Psychiatr 2012; 17: 236–237. · DOI · Paper page
  4. Beevers CG, McGeary JE . Therapygenetics: moving towards personalized psychotherapy treatment. Trends Cogn Sci 2012; 16: 11–12. · DOI
  5. Eid M, Riemann R, Angleitner A, Borkenau P . Sociability and positive emotionality: genetic and environmental contributions to the covariation between different facets of extraversion. J Pers 2003; 71: 319–346. · DOI · Paper page
  6. Dreher JC, Kohn P, Kolachana B, Weinberger DR, Berman KF . Variation in dopamine genes influence responsivity of the human reward system. Proc Natl Acad Sci USA 2009; 106: 617–622. · DOI · Paper page
  7. Costa e Silva JA . Personalized medicine in psychiatry: new technologies and approaches. Metabolism 2013; 62: 25. · DOI
  8. Arias-Carrión O, Stamelou M, Murillo-Rodríguez E, Menéndez-González M, Pöppel E . Dopaminergic reward system: a short integrative review. Int Arch Med 2010; 3: 24–29. · DOI · Paper page
  9. Haber SN, Knutson B . The reward circuit: Linking primate anatomy and human imaging. Neuropsychopharmacology 2010; 35: 4–26. · DOI · Paper page
  10. Kelly AE, Berridge KC . The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci 2002; 22: 3306–3311. · DOI · Paper page
  11. Di Chiara G, North RA . Neurobiology of opiate abuse. Trends Pharmacol Sci 1992; 13: 185–193. · DOI · Paper page
  12. Van Ree JM, Gerrits MAFM, Vanderschuren LJMJ . Opioids, reward and addicition: an encounter of biology, psychology and medicine. Pharmacol Rev 1999; 5: 341–396. · DOI · Paper page
  13. Dilts RP, Kalivas PW . Autoradiographic localization of mu-opioid and neurotensin receptors within the mesolimbic dopamine system. Brain Res 1989; 488: 311–327. · DOI
  14. Dilts RP, Kalivas PW . Autodiographic localization of delta opioid receptors within the mesocorticolimbic dopamine system using radioioidinated [2-D-penicillamine, 5-D-penicillamine] enkephalin (125I-DPDPE). Synapse 1990; 6: 121–132. · DOI
  15. Lester KJ, Eley TC . Therapygenetics: using genetic markers to predict response to psychological treatment for mood and anxiety disorders. Biol Mood Anxiety Disord 2013; 3: 2045–5380. · DOI · Paper page
  16. Moffit TE, Caspi A, Rutter M . Measured gene-environment interactions in psychopathology: concepts, research strategies, and implications for research, intervention, and public understanding of genetics. Persp Psychol Sci 2006; 1: 5–27. · DOI · Paper page
  17. Bogdan R, Nikolova YS, Pizzagalli DA . Neurogenetics of depression: a focus on reward processing and stress sensitivity. Neurobiol Disord 2013; 52: 12–23. · DOI · Paper page
  18. Hasler G, Drevets WC, Manji HK, Charney DS . Discovering endophenotypes for major depression. Neuropsychopharmacology 2004; 29: 1765–1781. · DOI · Paper page
  19. Delespaul PAEG. Assessing Schizophrenia in Daily Life: the Experience Sampling Method. Maastricht University Press: Maastricht, The Netherlands, 2005.
  20. Hamilton M . A rating scale for depression. J Neurol Neurosurg Psychiatr 1960; 23: 56–62. · DOI · Paper page
  21. First MB, Spitzer RL, Gibbon M, Willims JBW . Structured Clinical Interview for DSM-IV-TR Axis 1 Disorders, Research Version. Biometrics Research, New York State Psychiatric Institute: New York, NY, USA 2002.
  22. Segal ZV, Williams JMG, Teasdale JD . Mindfulness-based Cognitive Therapy for Depression: a new Approach to Preventing Relapse. Guilford Press: New York, NY, USA, 2002.
  23. Csikszentmihalyi M, Larson R . Validity and reliability of the experience sapling method. J Nerv Ment Dis 1987; 175: 526–536. · DOI · Paper page
  24. Ben Zion IZ, Tessler R, Cohen L, Lerer E, Raz Y, Bachner-Melman R et al. Polymorphisms in the dopamine D4 receptor gene (DRD4) contribute to individual differeneces in human sexual behavior: desire, arousal and sexual function. Mol Psychiatry 2006; 11: 782–786. · DOI
  25. Licinio J, Dong C, Wong M-L . Novel sequenc variations in the Brain-Derived Neurotrophic Factor gene and association with major depression and antidepresant treatment response. Arch Gen Psychiatry 2009; 66: 488–497. · DOI · Paper page
  26. Wang JC, Hinrichs AL, Stock H, Budde J, Allen R, Bertelsen S et al. Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome. Hum Mol Genet 2004; 13: 1903–1911. · DOI · Paper page
  27. Kraschewski A, Reese J, Anghelescu I, Winterer G, Schmidt LG, Gallinat J et al. Association of the dopamine D2 receptor gene with alcohol dependence: haplotypes and subgroups of alcoholics as key factors for understanding receptor function. Pharmacogenet Genomics 2009; 19: 513–527. · DOI
  28. Balciuniene J, Emilsson L, Oreland L, Pettersson U, Jazin EE . Investigation of the functional effect of monoamine oxidase polymorphisms in human brain. Hum Genet 2002; 110: 1–7. · DOI · Paper page
  29. Zhang H, Luo X, Kranzler HR, Lappalainen J, Yang B-Z, Krupitsky E et al. Association between two μ-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Human Mol Genet 2006; 15: 807–819. · DOI · Paper page
  30. Shabalina S, Zaykin DV, Gris P, Ogurtsov AY, Gauthier J, Shibata K et al. Expansion of the human μ-opioid receptor gene architecture: Novel functional variants. Hum Mol Genet 2008; 18: 1037–1051. · DOI · Paper page
  31. Azzato EM, Morton LM, Bergen AW, Wang SS, Chatterjee N, Kvale P et al. SLC6A3 and body mass index in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. BMC Med Genet 2009; 10: 9–17. · DOI
  32. Snijders T, Bosker R . Multilevel Analysis: an Introduction to Basis and Advanced Multilevel Modeling. Sage: London, UK, 1999.
  33. Faes C, Molenberghs G, Aerts M, Verbeke G . The effective sample size and an alternative small-sample degrees-of-freedom method. Am Stat 2009; 63: 389–399. · DOI
  34. Snijders TAB, Bosker RJ . Design effects in two-stage samples. Multilevel Analysis: an Introduction to Basic and Advanced Multilevel Modeling. Sage Publishers: London, 1999, pp 22–24.
  35. Clayton D Hill M . Wald tests. In: Clayton D, Hill M (eds). Statistical Models in Epidemiology. Oxford Science: Oxford, England, 1993, pp 101–102.
  36. Holm S . A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6: 65–70.
  37. Troisi A, Frazzetto G, Carola V, Di Lorenzo G, Coviello M, Siracusano A et al. Variation in the μ-opioid receptor gene (OPRM1) moderates the influence of early maternal care on fearful attachment. Soc Cogn Affect Neurosci 2012; 7: 542–547. · DOI · Paper page
  38. Wise RA The dopamine synapse and the notion of 'pleasure centers' in the brain. Trends Neurosci 1980; 3: 91–95. · DOI · Paper page
  39. Berridge K . The debate over dopamine’s role in reward: the case for incentive salience. Psychopharmacology 2007; 191: 391–431. · DOI · Paper page
  40. Berridge KC . Food reward: brain substrates of wanting and liking. Neurosci Biobehav Rev 1996; 20: 1–25. · DOI · Paper page
  41. Wise RA . Dual roles of dopamine in food and drug seeking: the drive-reward paradox. Biol Psychiatry 2013; 73: 819–826. · DOI · Paper page
  42. Peciña S . Opioid reward ‘liking’ and ‘wanting’ in the nucleus accumbens. Physiol Behav 2008; 94: 675–680. · DOI
  43. Cordeira JW, Frank L, Sena-Esteves M, Pothos EN, Rios M . Brain-derived neurotrophic factor regulates hedonic feeding by acting on the mesolimbic dopamine system. J Neurosci 2010; 30: 2533–2541. · DOI · Paper page
  44. Berton O, McClung CA, DiLeone RJ, Krishnan V, Renthal W, Russo SJ et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006; 31: 864–868. · DOI · Paper page
  45. Nestler EJ, Carlezon WA Jr . The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006; 59: 1151–1159. · DOI · Paper page
  46. Luo X, Kranzler HR, Zuo L, Wang S, Blumberg HP, Gelernter J . CHRM2 gene predisposes to alcohol dependence, drug dependence and affective disorders: results from an extended case-control structured association study. Hum Mol Genet 2005; 14: 2421–2434. · DOI · Paper page
  47. Cohen-Woods S, Gaysin D, Craddock N, Farmer A, Gray J, Gunasinghe C et al. Depression Case Control (DeCC) Study fails to support involvement of the muscarinic acetylcholine receptor M2 (CHRM2) gene in recurrent major depressive disorder. Hum Mol Genet 2009; 18: 1504–1509. · DOI · Paper page
  48. Jung MH, Park BL, Lee B-C, Ro Y, Park R, Shin HD et al. Association of CHRM2 polymorphisms with severity of alcohol dependence. Genes Brain Behav 2011; 10: 256–256. · DOI
  49. Gibbons AS, Scarr E, McLean C, Sundram S, Dean B . Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. J Affect Disord 2009; 116: 184–191. · DOI · Paper page
  50. Lai JH, Zhu YS, Huo ZH, Sun RF, Yu B, Wang YP et al. Association study of polymorphisms in the promoter region of DRD4 with schizophrenia, depression, and heroin addiction. Brain Res 2010; 1359: 227–232. · DOI
  51. Stice E, Yokum S, Zald D, Dagher A . Dopamine-based reward circuitry responsivity, genetics, and overeating. Curr Top Behav Neurosci 2011; 6: 81–93. · DOI
  52. Roses AD . Pharmacogenetics and the practice of medicine. Nature 2000; 405: 857–865. · DOI · Paper page
  53. Lonsdorf T, Ruck C, Bergstrom J, Andersson G, Ohman A, Lindefors N et al. The COMTval158met polymorphism is associated with symptom relief during exposure-based cognitive-behavioral treatment in panic disorder. BMC Psychiatry 2010; 10: 99. · DOI · Paper page
  54. Reif A, Richter J, Straube B, Hofler M, Lueken U, Gloster AT et al. MAOA and mechanisms of panic disorder revisited: from bench to molecular psychotherapy. Mol Psychiatry 2013; 19: 122–128. · DOI
  55. Fullana MA, Alonso P, Gratacos M, Jaurrieta N, Jimenez-Murcia S, Segalas C et al. Variation in the BDNF Val66Met polymorphism and response to cognitive-behavior therapy in obsessive-compulsive disorder. Eur Psychiatry 2012; 27: 386–390. · DOI · Paper page
  56. Bockting CL, Mocking RJ, Lok A, Koeter MW, Schene AH . Therapygenetics: the 5HTTLPR as a biomarker for response to psychological therapy? Mol Psychiatry 2012; 3: 92.
  57. Owen DR, Rupprecht R, Nutt DJ . Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety? J Psychopharmacol 2013; 27: 119–122. · DOI
  58. Höhn P, Menne-Lothmann C, Peeters F, Nicolson NA, Jacobs J, Derom C et al. Moment-to-moment transfer of positive emotions in daily life predicts future course of depression in both general population and patient samples. PLoS One 2013; 8: e75655. · DOI · Paper page
  59. Harmon-Jones E, Gable P, Price TF . The influence of affective states varying in motivational intensity on cognitive scope. Front Integr Neurosci 2012; 10: 73.
  60. Villafuerte S, Heitzeg MM, Foley S, Yau WY, Majczenko K, Zubieta JK et al. Impulsiveness and insula activation during reward anticipation are associated with genetic variants in GABRA2 in a family sample enriched for alcoholism. Mol Psychiatry 2012; 17: 511–519. · DOI · Paper page
  61. Grigorenko EL . Epistasis and the genetics of complex traits. In: Plomin R, DeFries J, Craig IW, McGuffin P (eds). Behavioural Genetics in the Postgenomic Era. American Psychological Association: Washington, DC, USA, 2003, pp 247–266. · doi:10.1037/10480-014

Cited by

See all 22

Metadata

Authors
Bakker, J. M., Lieverse, R., Menne-Lothmann, C., Viechtbauer, W., Pishva, E., Kenis, G., Geschwind, N., Peeters, F., van Os, J., & Wichers, M.
Venue
Translational Psychiatry
Published
2014-04-22
Volume
4
Issue
4
Pages
e384-e384
ISSN
2158-3188 (ISSN-L)
OpenAlex
W1969537204
Cited by
22
References
29
FWCI
4.13
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.